

Peripheral Vascular Devices Market by Type (Angioplasty Balloon & Stent, Catheters, Endovascular Aneurysm Repair Stent Grafts, Plaque Modification Devices, Hemodynamic flow alteration devices), Region - Forecast to 2029

Market Report | 2025-03-01 | 325 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global Peripheral vascular devices market is projected to reach USD 14.73 billion by 2029 from USD 11.43 billion in 2024, at a CAGR of 5.2% from 2024 to 2029. The market for peripheral vascular devices is sharply increasing in view of an increased prevalence of vascular diseases such as PAD and DVT. Other key drivers for this expansion are an aging population base, increased adoption of less-invasive procedures, and advancements in vascular technology in stents, angioplasty balloons, and catheters. Increased awareness about timely diagnosis and treatment options and supportive initiatives from the government further increase market demand. Improvement in global healthcare infrastructure and an increased number of specialized vascular clinics are adding to upward movement of the market.

"By type segment Angioplasty stent to account for the largest share during the forecast period"

The peripheral vascular devices market offers a higher share of stents used in the treatment of angioplasty mainly because stenting is vital in managing diseases such as PAD and CAD. Stents are designed to give long-term vessel support where by the lumen of the arteries needs to be maintained after having a balloon angioplasty. Unlike balloons or catheters, stents are not used only during procedures; they are a permanent solution to the narrowing of an artery, decreasing the chances of restenosis.

Technological advancements employing drug-eluting stents (DES) and bioresorbable stents have enhanced the capability of stents by lowering complications and yielding a better prognosis in the long term, therefore making it highly popular.

Stents are also increasingly gaining popularity because they are minimally invasive, where time towards recovery by patients and even the number of days spent in hospitals can be reduced compared to EVAR, or Endovascular Aneurysm Repair traditional surgical methods. Moreover, since the incidence of cardiovascular diseases and pay policies on stent procedures are rapidly moving in a healthy and benign direction, stent stints take the lead. Moreover, given the large geriatric population, where

Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

revascularization needs keep soaring, angioplasty stents remain the market leader for peripheral vascular devices.

"APAC is estimated to register the highest CAGR during the forecast period."

The Peripheral vascular devices market is divided into Five regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific region witnessed the highest CAGR during the forecast period. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. The increasing diabetic population and increase in obesity due to sedentary lifestyles reassesses also driving the growth of peripheral vascular devices in the APAC region.

The breakdown of the profile of primary participants in the peripheral vascular devices market:

- -∏By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
- -□By Designation: C-level Executives- 35%, Directors- 25%, and Others- 40%.
- -¬By Region: North America 40%, Europe 30%, APAC -20%, Latin America 5%, Middle East & Africa-5%

List of Companies Profiled in the Report

- -□Boston scientific corporation(U.S)
- -□Medtronic (U.S)
- -□Abbott (U.S)
- -□Becton, Dickinson, and Company(U.S)
- Terumo Corporation (Japan)
- -□B. Braun Melsungen AG(Germany)
- Merit medical systems(U.S)
- ¬Penumbra, inc.(U.S)
- -□Koninklijke Philips N.V..(Japan)

Research Coverage

This report studies the Peripheral vascular devices market based on type and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total Peripheral vascular devices market. The report forecasts the revenue of the market segments to five major regions.

Reasons to Buy the Report

This report also includes.

- Analysis of key drivers (technological advancements), restraints (Cost of the system), challenges (regulatory policies), and opportunities (Increase in minimally invasive procedures) contributing to the growth of the Peripheral vascular devices market. Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Peripheral
- vascular devices market.
- $\verb|-|| Market Development: Comprehensive information on the lucrative emerging markets type and region.$
- Market Diversification: Exhaustive information about the growing geographies, recent developments, and investments in the Peripheral vascular devices market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Peripheral vascular devices market.

Table of Contents:

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28

Scotts International, EU Vat number: PL 6772247784

- 1.2 MARKET DEFINITION 28
- 1.3 MARKET SCOPE 29
- 1.3.1 MARKET SEGMENTATION 29
- 1.3.2 INCLUSIONS & EXCLUSIONS 30
- 1.3.3 YEARS CONSIDERED 30
- 1.3.4 CURRENCY CONSIDERED 30
- 1.4□LIMITATIONS□31
- 1.5 MARKET STAKEHOLDERS 31
- 1.6 SUMMARY OF CHANGES 32
- 2∏RESEARCH METHODOLOGY∏33
- 2.1 RESEARCH DATA 33
- 2.1.1∏SECONDARY DATA∏34
- 2.1.1.1 Key data from secondary sources 35
- 2.1.2□PRIMARY DATA□36
- 2.1.2.1 Key data from primary sources 37
- 2.1.2.2 Key industry insights 37
- 2.2 MARKET SIZE ESTIMATION 38
- 2.3 MARKET BREAKDOWN & DATA TRIANGULATION 43
- 2.4 MARKET SHARE ANALYSIS 44
- 2.5∏STUDY ASSUMPTIONS∏44
- 2.6 RISK ASSESSMENT 44
- 2.7 RESEARCH LIMITATIONS 45
- 2.7.1 METHODOLOGY-RELATED LIMITATIONS ☐ 45
- 3∏EXECUTIVE SUMMARY∏46
- 4□PREMIUM INSIGHTS□51
- 4.1 □ PERIPHERAL VASCULAR DEVICES MARKET OVERVIEW □ 51
- 4.2 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE AND COUNTRY (2023) □52
- 4.3 PERIPHERAL VASCULAR DEVICES MARKET: GEOGRAPHIC SNAPSHOT 52

- 5∏MARKET OVERVIEW∏53
- 5.1 INTRODUCTION 53
- 5.2 MARKET DYNAMICS 153
- 5.2.1□DRIVERS□54
- 5.2.1.1 Rapid growth in geriatric population and subsequent increase in disease prevalence 54
- 5.2.1.2 Favorable reimbursement scenario for procedures 54
- 5.2.1.3 Increased prevalence of diabetes ☐ 55
- 5.2.1.4 Rising rate of tobacco consumption 56
- 5.2.1.5 Growing incidence of obesity 56
- 5.2.2□OPPORTUNITIES□57
- 5.2.2.1 High growth potential in emerging markets 57
- 5.2.3 CHALLENGES 58
- 5.2.3.1 Availability of alternative treatments 58
- 5.2.3.2 Dearth of skilled professionals with expertise in peripheral vascular devices 58
- 5.2.3.3 Product failures and recalls 58
- 5.3□INDUSTRY TRENDS□59
- 5.4∏ECOSYSTEM ANALYSIS∏59
- 5.5 VALUE CHAIN ANALYSIS 60

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.6 SUPPLY CHAIN ANALYSIS 61
- 5.7 PORTER'S FIVE FORCE ANALYSIS 62
- 5.7.1 THREAT OF NEW ENTRANTS 63
- 5.7.2 THREAT OF SUBSTITUTES 63
- 5.7.3 BARGAINING POWER OF SUPPLIERS 63
- 5.7.4 BARGAINING POWER OF BUYERS 63
- 5.7.5 INTENSITY OF COMPETITIVE RIVALRY 63
- 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 64
- 5.8.1 KEY STAKEHOLDERS 64
- 5.8.2 BUYING CRITERIA 65
- 5.9 □ TECHNOLOGY ANALYSIS □ 66
- 5.9.1 | KEY TECHNOLOGIES | 66
- 5.9.1.1 Drug-eluting stents 66
- 5.9.1.2 Atherectomy devices 66
- 5.9.2 COMPLEMENTARY TECHNOLOGIES 66
- 5.9.2.1∏Intravascular ultrasound∏66
- 5.9.2.2 Optical coherence tomography 66
- 5.9.3∏ADJACENT TECHNOLOGIES∏66
- 5.9.3.1 Remote patient monitoring 66

- 5.10 REGULATORY LANDSCAPE 67
- 5.10.1 REGULATORY ANALYSIS 67
- 5.10.1.1 North America 67
- 5.10.1.1.1 US 67
- 5.10.1.1.2 Canada 67
- 5.10.1.2 Europe 68
- 5.10.1.3∏Asia Pacific∏68
- 5.10.1.3.1 | Japan | 68
- 5.10.1.3.2 China 68
- 5.10.2 ⊓REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS ∏69
- 5.11 TRADE ANALYSIS 71
- 5.11.1 IMPORT DATA I 72
- 5.11.2 TEXPORT DATA T73
- 5.12 PRICING ANALYSIS 73
- 5.12.1 AVERAGE SELLING PRICE TREND, BY REGION 74
- 5.12.2 AVERAGE SELLING PRICE, BY KEY PLAYERS 74
- 5.13 REIMBURSEMENT ANALYSIS 75
- 5.14 PATENT ANALYSIS 78
- 5.14.1 PATENT PUBLICATION TRENDS 78
- 5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 79
- 5.15 KEY CONFERENCES AND EVENTS, 2024-2025 80
- 5.16 CASE STUDIES 81
- 5.16.1 CASE STUDY 1: DRUG-COATED BALLOON HELPING IN REDUCING RESTENOSIS 81
- 5.16.2 CASE STUDY 2: IMPROVED OUTCOMES WITH TERUMO'S MISAGO STENT 81
- 5.17 UNMET NEEDS AND END-USER EXPECTATIONS 182
- 5.17.1 UNMET NEEDS 82
- 5.17.2 END-USER EXPECTATIONS 82

Scotts International, EU Vat number: PL 6772247784

- 5.18 INVESTMENT & FUNDING SCENARIO 83
- 5.19 IMPACT OF AI ON PERIPHERAL VASCULAR DEVICES MARKET 84
- 6 PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 86
- 6.1□INTRODUCTION□87
- 7 ANGIOPLASTY STENTS MARKET, BY TYPE 88
- 7.1⊓INTRODUCTION⊓89
- 7.2 DRUG-ELUTING STENTS 91
- 7.2.1 DRUG-ELUTING STENTS TO WITNESS HIGHER ADOPTION 91
- 7.3 BARE-METAL STENTS 93
- 7.3.1 BARE-METAL STENTS, BY DELIVERY PLATFORM 95

- 7.3.1.1 Balloon-expandable stents 95
- 7.3.1.1.1 Better radial strength and ease of deployment to drive usage 95
- 7.3.1.2 Self-expandable stents 96
- 7.3.1.2.1 Flexibility, tolerance, and support for vessel movement and compression to propel market 96
- 8□ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY TYPE□98
- 8.1□INTRODUCTION□99
- 8.2 ☐ ABDOMINAL AORTIC ANEURYSM STENT GRAFTS ☐ 100
- 8.2.1 RISING PREVALENCE AND NEED FOR TREATMENT TO DRIVE MARKET 100
- 8.3 THORACIC AORTIC ANEURYSM STENT GRAFTS 102
- 8.3.1 INCREASING INCIDENCE OF THORACIC AORTIC ANEURYSMS TO PROPEL ADOPTION 102
- 9 CATHETERS MARKET, BY TYPE 103
- 9.1∏INTRODUCTION∏104
- 9.2 ANGIOGRAPHY CATHETERS 105
- 9.2.1 ANGIOGRAPHY CATHETERS TO DOMINATE CATHETERS MARKET 105
- 9.3 GUIDING CATHETERS 107
- 9.3.1 GROWING NUMBER OF TARGET PROCEDURES TO DRIVE MARKET 107
- 9.4□IVUS/OCT CATHETERS□108
- 9.4.1 IVUS/OCT CATHETERS SEGMENT TO REGISTER HIGHEST GROWTH 108
- 10∏INFERIOR VENA CAVA FILTERS MARKET, BY TYPE∏110
- 10.1 INTRODUCTION 111
- 10.2 RETRIEVABLE FILTERS 113
- 10.2.1 ⊓RETRIEVABLE FILTERS SEGMENT TO REGISTER HIGHER GROWTH □113
- 10.3 PERMANENT FILTERS 114
- 10.3.1 RISKS ASSOCIATED WITH PERMANENT FILTERS TO HAMPER SALES 114
- 11 ANGIOPLASTY BALLOONS MARKET, BY TYPE 115
- 11.1 INTRODUCTION 116
- 11.2 OLD/NORMAL BALLOONS 117
- 11.2.1 OLD/NORMAL BALLOONS TO DOMINATE ANGIOPLASTY BALLOONS MARKET 11.7
- 11.3 DRUG-ELUTING BALLOONS 119
- 11.3.1 DRUG-ELUTING BALLOONS TO WITNESS HIGHEST GROWTH 119
- 11.4 CUTTING & SCORING BALLOONS 121
- $11.4.1 \verb||| PREFERENCE FOR MEDICATION AS PRIMARY TREATMENT FOR ATHEROSCLEROSIS TO RESTRAIN ADOPTION \verb||| 121 || 122 || 123 || 124 || 124 || 125 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 || 126 ||$
- 12 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 123
- 12.1 INTRODUCTION 124
- 12.2 ATHERECTOMY DEVICES 126

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.1 INCREASING INCIDENCE OF ATHEROSCLEROSIS TO DRIVE MARKET 126
- 12.3 THROMBECTOMY DEVICES 127
- 12.3.1 GROWING DVT INCIDENCE TO DRIVE ADOPTION OF THROMBECTOMY DEVICES 127
- 13 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 129
- 13.1□INTRODUCTION□130
- 13.2∏EMBOLIC PROTECTION DEVICES∏130
- 13.2.1 INVESTMENTS IN TECHNOLOGICAL ADVANCEMENTS AND GROWING REGULATORY APPROVALS TO DRIVE MARKET 130
- 13.3 CHRONIC TOTAL OCCLUSION DEVICES 132
- 13.3.1 RISING SUPPORT FOR DEVICE DEVELOPMENT TO DRIVE MARKET 132
- 14∏OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE∏134
- 14.1∏INTRODUCTION∏135
- 14.2 GUIDEWIRES □137
- 14.2.1 GUIDEWIRES TO HOLD LARGEST MARKET SHARE 137
- 14.3 VASCULAR CLOSURE DEVICES 138
- 14.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 138
- 14.4 INTRODUCER SHEATHS 140
- 14.4.1 POTENTIAL FOR REDUCING ARTERIAL DAMAGE TO DRIVE ADOPTION 140
- 14.5 BALLOON INFLATION DEVICES 141
- 14.5.1 INTEGRATED TECHNOLOGIES AND RISING NUMBER OF TARGET PROCEDURES TO PROPEL ADOPTION 141
- 15 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION 142
- 15.1 INTRODUCTION 143
- 15.2 NORTH AMERICA 144
- 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 145
- 15.2.2∏US∏148
- 15.2.2.1 Favorable reimbursement scenario to contribute to growth 148
- 15.2.3 CANADA 152
- 15.2.3.1 ☐Increasing cases of chronic conditions to fuel market ☐152
- 15.3∏EUROPE∏155
- 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 155
- $15.3.2 \square GERMANY \square 159$
- 15.3.2.1 Statutory health insurance policy to support growth 159
- 15.3.3∏FRANCE∏162
- ?
- 15.3.4∏UK∏166
- $15.3.4.1 \verb|| Increasing volume of coronary angioplasty procedures to sustain growth \verb||| 166$
- 15.3.5 SPAIN 169
- 15.3.5.1 Growing cases of diabetes and obesity to boost market 169
- 15.3.6□ITALY□173
- 15.3.6.1 ☐Increasing prevalence of atherosclerotic cardiovascular disease to spur growth ☐173
- 15.3.7 REST OF EUROPE 176
- 15.4□ASIA PACIFIC□180
- 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 180
- 15.4.2∏JAPAN∏185
- 15.4.2.1 Large geriatric population to ensure sustained demand 185
- $15.4.3 \verb||CHINA|| 188$
- 15.4.3.1 Growing incidence of lifestyle diseases to fuel market 188

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.4.4 INDIA 191
- 15.4.4.1 Rising prevalence of target diseases and growing healthcare expenditure to propel market 191
- 15.4.5 AUSTRALIA 195
- 15.4.5.1 High prevalence of cardiovascular and peripheral artery diseases to drive market 195
- 15.4.6 SOUTH KOREA 198
- 15.4.6.1 Rising rates of chronic diseases to boost market 198
- 15.4.7 REST OF ASIA PACIFIC 202
- 15.5 LATIN AMERICA 205
- 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 205
- 15.5.2 BRAZIL 208
- 15.5.2.1 Rising healthcare expenditure to aid growth 208
- 15.5.3 | MEXICO | 212
- 15.5.3.1 ☐Increasing prevalence of cardiovascular diseases to spur growth ☐212
- 15.5.4□COLOMBIA□215
- 15.5.4.1 Growing incidence of peripheral artery diseases to expedite growth 215
- 15.5.5 □ ARGENTINA □ 218
- 15.5.5.1 □Increasing prevalence of peripheral artery diseases to support market growth □218
- 15.5.6 REST OF LATIN AMERICA 221
- 15.6 MIDDLE EAST & AFRICA 224
- 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 225
- 15.6.2 GCC COUNTRIES 228
- 15.6.2.1 Rising cases of hypertension and associated cardiovascular diseases to drive market 228
- 15.6.3 REST OF MIDDLE EAST & AFRICA 231

- 16 COMPETITIVE LANDSCAPE 235
- 16.1□INTRODUCTION□235
- 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 235
- 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 235
- 16.3 REVENUE ANALYSIS 236
- 16.4 MARKET SHARE ANALYSIS 237
- 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 239
- 16.5.1 | STARS | 239
- 16.5.2∏EMERGING LEADERS∏239
- 16.5.3 PERVASIVE PLAYERS □ 239
- 16.5.4 PARTICIPANTS 239
- 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 241
- 16.5.5.1 Company footprint 241
- 16.5.5.2 Type footprint 242
- 16.5.5.3 Region footprint 243
- 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 244
- 16.6.1 PROGRESSIVE COMPANIES 244
- 16.6.2 DYNAMIC COMPANIES 244
- 16.6.3 RESPONSIVE COMPANIES 244
- 16.6.4 STARTING BLOCKS 244
- 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 246
- 16.7 BRAND/PRODUCT COMPARISON 247
- 16.8 COMPANY VALUATION AND FINANCIAL METRICS 248

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.8.1 FINANCIAL METRICS 248
- 16.8.2 COMPANY VALUATION 248
- 16.9 COMPETITIVE SCENARIO 249
- 16.9.1 PRODUCT LAUNCHES AND APPROVALS 249
- 16.9.2 DEALS 250
- 17□COMPANY PROFILES□252
- 17.1 KEY PLAYERS 252
- 17.1.1 BOSTON SCIENTIFIC CORPORATION 252
- 17.1.1.1 Business overview 252
- 17.1.1.2 Products offered 253
- 17.1.1.3 Recent developments 255
- 17.1.1.3.1 Product approvals 255
- 17.1.1.3.2 Deals 256
- 17.1.1.3.3 Other developments 256
- 17.1.1.4 MnM view 257
- 17.1.1.4.1 Right to win 257
- 17.1.1.4.2 Strategic choices 257
- 17.1.1.4.3 Weaknesses and competitive threats 257
- 17.1.2 MEDTRONIC 258
- 17.1.2.1 Business overview 258
- 17.1.2.2 Products offered 259
- 17.1.2.3 Recent developments 261
- 17.1.2.3.1 Product launches & product approvals 261
- $17.1.2.3.2 \verb|| Deals \verb||| 262$
- 17.1.2.4 MnM view 262
- 17.1.2.4.1 Right to win 262
- 17.1.2.4.2

 ☐ Strategic choices

 ☐ 262
- 17.1.2.4.3 Weaknesses and competitive threats 262
- 17.1.3 ABBOTT 263
- 17.1.3.1 Business overview 263
- 17.1.3.2 Products offered 264
- 17.1.3.3 Recent developments 266
- 17.1.3.3.1 Product launches 266
- 17.1.3.3.2∏Deals∏266
- 17.1.3.4 MnM view 267
- 17.1.3.4.1 Right to win 267
- 17.1.3.4.2 Strategic choices made 267
- 17.1.3.4.3 Weaknesses and competitive threats 267
- 17.1.4 BECTON, DICKINSON AND COMPANY 268
- 17.1.4.1 Business overview 268
- 17.1.4.2 Products offered 269
- 17.1.4.3 Recent developments 271
- 17.1.4.3.1 Product launches and product approvals 271
- 17.1.4.3.2 Deals 272
- 17.1.4.3.3 Other developments 273
- 17.1.4.4 MnM view 273
- 17.1.4.4.1 Right to win 273

Scotts International, EU Vat number: PL 6772247784

- 17.1.4.4.2 Strategic choices 273
- 17.1.4.4.3 Weaknesses and competitive threats 273
- 17.1.5 TERUMO CORPORATION 274
- 17.1.5.1 Business overview 274
- 17.1.5.2 Products offered 275
- 17.1.5.3 Recent developments 276
- 17.1.5.3.1 Product launches 276
- 17.1.5.4 MnM view 277
- 17.1.5.4.1 Right to win 277
- 17.1.5.4.2 Strategic choices 277
- 17.1.5.4.3 Weaknesses and competitive threats 277

- 17.1.6 B. BRAUN SE 278
- 17.1.6.1 Business overview 278
- 17.1.6.2 Products offered 279
- 17.1.6.3 Recent developments 281
- 17.1.6.3.1 Product approvals 281
- 17.1.7 MERIT MEDICAL SYSTEMS 282
- 17.1.7.1 Business overview 282
- 17.1.7.2 Products offered 283
- 17.1.7.3 Recent developments 284
- 17.1.7.3.1 Product launches 284
- 17.1.7.3.2 | Deals | 284
- 17.1.8 PENUMBRA, INC. 285
- 17.1.8.1 Business overview 285
- 17.1.8.2 Products offered 286
- 17.1.8.3 Recent developments 287
- 17.1.8.3.1 Product launches and product approvals 287
- 17.1.9 KONINKLIJKE PHILIPS NV 288
- 17.1.9.1 Business overview 288
- 17.1.9.2 Products offered 289
- 17.1.9.3 Recent developments 290
- $17.1.9.3.1 \verb|| Product approvals \verb||| 290$
- 17.1.9.3.2 Deals 290
- 17.1.10 STRYKER 291
- 17.1.10.1 Business overview 291
- 17.1.10.2 Products offered 292
- 17.1.10.2.1 Deals 293
- 17.1.11 CORDIS 294
- 17.1.11.1 Business overview 294
- 17.1.11.2 Products offered 294
- 17.1.11.3 Recent developments 296
- 17.1.11.3.1 Product approvals 296
- 17.1.11.3.2 Deals 296
- 17.1.11.3.3 Other developments 296
- 17.1.12 COOK 297
- 17.1.12.1 Business overview 297

Scotts International. EU Vat number: PL 6772247784

- 17.1.12.2 Products offered 297
- 17.1.12.3 Recent developments 299
- 17.1.12.3.1 Deals 299
- 17.1.13 W. L. GORE & ASSOCIATES, INC. 300
- 17.1.13.1 Business overview 300
- 17.1.13.2 Products offered 300
- 17.1.13.3 Recent developments 302
- 17.1.13.3.1 Product approvals 302
- 17.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD. 303
- 17.1.14.1 Business overview 303
- 17.1.14.2 Products offered 303
- 17.1.15 IVASCULAR I 304
- 17.1.15.1 Business overview 304
- 17.1.15.2 Products offered 304
- 17.1.16 BIOTRONIK 305
- 17.1.16.1 Business overview 305
- 17.1.16.2 Products offered 305
- 17.1.16.3 Recent developments 306
- 17.1.16.3.1 Product launches 306
- 17.1.17∏ENDOLOGIX∏307
- 17.1.17.1 Business overview 307
- 17.1.17.2 Products offered 307
- 17.1.18 ENDOCOR GMBH & CO., KG 308
- 17.1.18.1 Business overview 308
- 17.1.18.2 Products offered 308
- 17.2□OTHER PLAYERS□309
- 17.2.1 MERIL LIFE SCIENCES PVT. LTD. 309
- 17.2.2∏ALVIMEDICA∏310
- 17.2.3 CARDIONOVUM GMBH 311
- 17.2.4∏SMT∏311
- 17.2.5 MEDINOL 312
- 17.2.6∏ANDRAMED GMBH∏312
- 17.2.7 REX MEDICAL 313
- 17.2.8 QMD INC. 313
- 17.2.9 BROSMED MEDICAL CO., LTD. 314
- 17.2.10 ELIXIR MEDICAL 315
- 18 APPENDIX 316
- 18.1 DISCUSSION GUIDE 316
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 321
- 18.3 CUSTOMIZATION OPTIONS 323
- 18.4 RELATED REPORTS 323
- 18.5 AUTHOR DETAILS 324



To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

☐ - Print this form

Peripheral Vascular Devices Market by Type (Angioplasty Balloon & Stent, Catheters, Endovascular Aneurysm Repair Stent Grafts, Plaque Modification Devices, Hemodynamic flow alteration devices), Region - Forecast to 2029

Market Report | 2025-03-01 | 325 pages | MarketsandMarkets

	nned email to support@scotts-internation	nai.com	
ORDER FORM:			
Select license	License		Price
	Single User		\$4950.00
	Multi User		\$6650.00
	Corporate License		\$8150.00
	Enterprise Site License		\$10000.00
		VAT	
		Tota	I
J. VAT WIII be added	at 23 % for Folish based Companies, individue	als and EII based companies who are unable to provide a	394 346.
≣mail*		als and EU based companies who are unable to provide a	
	į.	Phone*	
First Name*	į.	<u></u>	
First Name*	į.	Phone*	
Email* First Name* ob title* Company Name*		Phone*	
First Name* ob title*		Phone* Last Name*	

Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com

Date	2025-05-06
C'anah	
Signature	